Ultragenyx announces Health Canada extended approval of Evkeeza

Ultragenyx (RARE) Pharmaceutical announced that Health Canada has extended the approval of Evkeeza as an adjunct to diet and other low-density lipoprotein cholesterol, LDL-C, lowering therapies to treat children aged 6-months and older with homozygous familial hypercholesterolemia, HoFH. Evkeeza, an angiopoietin-like 3, ANGPTL3, inhibitor initially received Health Canada approval in September 2023 as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with HoFH, a disease associated with dangerously high levels of LDL-C.